Karyopharm Therapeutics (KPTI) EBT Margin (2012 - 2026)
Karyopharm Therapeutics (KPTI) reported EBT Margin of -200.48% for Q2 2026, down 102.37 percentage points from -98.11% a year earlier.
Powered by 
Analysis
Karyopharm Therapeutics (KPTI) EBT Margin (2012 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Karyopharm Therapeutics' EBT Margin came in at -160.28%, down 70.26 percentage points year-over-year; for FY2025, it was -134.18%, down 81.60 percentage points from FY2024.
- EBT Margin has a five-year change of +47.12 percentage points (FY2020 to FY2025).
- By year, EBT Margin came in at -52.58% in FY2024 (+45.19 pp), -97.77% in FY2023 (+7.23 pp), -105.00% in FY2022 (-45.98 pp) and -59.01% in FY2021 (+122.29 pp).
- Five-year quarterly EBT Margin spans a low of -300.08% in Q4 2025 and a high of 55.76% in Q2 2024.
- Year over year, EBT Margin gained in four of the last seven quarters, with an average year-over-year change of -53.94 percentage points.
- The high point for year-over-year EBT Margin in five years was Q1 2022 (a gain of 159.62 percentage points); the low point was Q4 2025 (a drop of 198.95 percentage points).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.01 Bn | 563.54 Bn | 17.26 Bn | 26.66% |
| 2 | AbbVie | 465.23 Bn | 438.39 Bn | 12.70 Bn | 25.18% |
| 3 | Merck | 368.40 Bn | 322.83 Bn | 12.21 Bn | -4.11% |
| 4 | Novartis Ag | 278.02 Bn | 233.89 Bn | 11.24 Bn | 29.63% |
| 5 | Astrazeneca | 254.57 Bn | 228.13 Bn | 12.86 Bn | 18.19% |
| 6 | Amgen | 229.02 Bn | 184.42 Bn | 7.24 Bn | 27.53% |
| 7 | Gilead Sciences | 187.74 Bn | 161.85 Bn | 6.22 Bn | -131.41% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | -4.34% |
| 9 | Vertex Pharmaceuticals | 133.45 Bn | 105.45 Bn | 2.84 Bn | 41.75% |
| 10 | Karyopharm Therapeutics | 35.01 Mn | -191.41 Mn | 32.35 Mn | -200.48% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -200.48% |
| Dec 31, 2025 | -300.08% |
| Sep 30, 2025 | -75.14% |
| Jun 30, 2025 | -98.11% |
| Mar 31, 2025 | -78.05% |
| Dec 31, 2024 | -101.14% |
| Sep 30, 2024 | -82.62% |
| Jun 30, 2024 | 55.76% |
| Mar 31, 2024 | -112.57% |
| Dec 31, 2023 | -123.59% |
| Sep 30, 2023 | -95.79% |
| Jun 30, 2023 | -86.49% |
| Mar 31, 2023 | -88.05% |
| Dec 31, 2022 | -114.45% |
| Sep 30, 2022 | -100.37% |
| Jun 30, 2022 | -123.34% |
| Mar 31, 2022 | -86.57% |
| Dec 31, 2021 | 30.57% |
| Sep 30, 2021 | -137.19% |
| Jun 30, 2021 | -236.49% |
API Access
Karyopharm Therapeutics EBT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebt-margin&ticker=KPTI&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebt-margin", "ticker": "KPTI", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebt-margin&ticker=KPTI&period=max&api_key=YOUR_API_KEY");
const data = await res.json();